@article{oai:niigata-u.repo.nii.ac.jp:00014723,
 author = {吉澤, 弘久 and 松本, 尚也 and 望月, 博史 and 栗山, 英之 and 各務, 博 and 鈴木, 栄一 and 下条, 文武},
 issue = {9},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Sep},
 note = {A phase I dose-escalation study of multicyclic, ifosfamide, carboplatin, and etoposide (ICE) with sequential reinfusion of peripheral blood stem-cells (PBSCs) was conducted to determine the maximum-tolerated dose (MTD) of ICE. Twenty-seven patients with SCLC (LD : 9, ED : 18) were treated with ifosfamide (3000-9000mg/m^2, 24-hour-infusion), carboplatin (300-400mg/m^2), and etoposide (300mg/m^2) followed by subcutaneous injection of filgrastim (75μg/day) through day 4 to the day of PBSC collection. PBSC were harvested when the WBC count reached ≧5×10^9/L. The leukapheresis product was cryopreserved and reinfused on day 4 of the next cycle, which was started 48 hours after the last PBSC collection. The ifosfamide dose was escalated as follows : 3000mg/m^2 (level 1), 5000mg/m^2 (level 2), 7000mg/m^2 (level 3), 9000mg/m^2 (level 4). Patients with LD were treated with concurrent radiotherapy at 1.5 Gy twice daily for the initial 3 weeks to a total dose of 45Gy and MTD, defined separately. Patients were evaluated for hematologic and non-hematologic toxicity, actual dose intensities, as well as response to the therapy. The maximum-tolerated dose (MTD) was defined as the dose level at which the level produced more than 5 days of grade 4 myelosuppression or non-hematologic toxicity greater than grade 3 in two thirds of the patients. For ED cases, MTD was level 4 and the recommended dose of ifosfamide was 7000mg/m^2. For LD cases, the recommended dose of ifosfamide was 5000mg/m^2. The dose limiting toxicity of multicyclic ICE was hematologic toxicity and CNS toxicity which manifested as ataxia. Tumor responses were seen in all patients, with 14 patients showing a complete response. The actual total dose-intensity at the recommended dose level was 2.2 and 1.74, for ED and LD, respectively, compared with previously reported ICE regimens. PBSC support for dose-intensive ICE regimen permitted dose escalation of ifosfamide with a mean interval of 16-17 days. We conclude this regimen is well tolerated, with acceptable hematological and non-hematological toxicity.},
 pages = {432--437},
 title = {2）小細胞肺癌に対する末梢血幹細胞移植併用(シンポジウム 移植医療の現況, 第551回新潟医学会)},
 volume = {115},
 year = {2001}
}